Seattle 2035 →
Partner at New Enterprise Associates
Managing Director, Mercury Fund
Executive Partner, Sofinnova Ventures
Co-Founder and CEO, DNAnexus
Founder and Chairman, Sycamore Networks
Founder and CEO, Lighter Capital
CEO and co-founder of BoostSuite
October 30, 2015 ·
November 17, 2015 ·
December 2, 2015 ·
NKT Therapeutics is developing drugs that target a class of immune cells known as natural killer T cells.
Xconomy offers a number of ways to subscribe for free!
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit/Ann Arbor, San Francisco, New York, Raleigh-Durham, Boulder/Denver, Texas, Wisconsin and beyond.
© 2007-2015, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Website development support from Andrew Koyfman with design support from Rob Hunter.